Action of methotrexate and tofacitinib on directly stimulated and bystander-activated lymphocytes

Piscianz,Elisa; Candilera,Vanessa; Valencic,Erica; Loganes,Claudia; Paron,Greta; De Iudicibus,Sara; Decorti,Giuliana; Tommasini,Alberto

doi:10.3892/mmr.2016.5263

Action of methotrexate and tofacitinib on directly stimulated and bystander-activated lymphocytes

Authors:
- Elisa Piscianz
- Vanessa Candilera
- Erica Valencic
- Claudia Loganes
- Greta Paron
- Sara De Iudicibus
- Giuliana Decorti
- Alberto Tommasini
View Affiliations

Affiliations: Department of Advanced Diagnostic and Clinical Trials, Institute for Maternal and Child Health, IRCCS ‘Burlo Garofolo’, I-34137 Trieste, Italy, Department of Medical, Surgical and Health Sciences, University of Trieste, I-34100 Trieste, Italy, Department of Life Sciences, University of Trieste, I-34100 Trieste, Italy, Department of Paediatrics, Institute for Maternal and Child Health, IRCCS ‘Burlo Garofolo’, I-34137 Trieste, Italy
Published online on: May 13, 2016 https://doi.org/10.3892/mmr.2016.5263
Pages: 574-582

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Chronic inflammation associated with autoimmune activation is characteristic of rheumatic diseases from childhood to adulthood. In recent decades, significant improvements in the treatment of these types of disease have been achieved using disease modifying anti-rheumatic drugs (DMARDs), such as methotrexate (MTX) and, more recently, using biologic inhibitors. The recent introduction of kinase inhibitors (for example, tofacitinib; Tofa) further increases the available ARDs. However, there are patients that do not respond to any treatment strategies, for whom combination therapies are proposed. The data regarding the combined action of different drugs is lacking and the knowledge of the mechanisms of ARDs and their actions upon pathogenic lymphocytes, which are hypothesized to sustain disease, is poor. An in vitro model of inflammation was developed in the current study, in which stimulated and unstimulated lymphocytes were cultured together, but tracked separately, to investigate the action of MTX and Tofa on the two populations. By analysing lymphocyte proliferation and activation, and cytokine secretion in the culture supernatants, it was established that, due to the presence of activated cells, unstimulated cells underwent a bystander activation that was modulated by the ARDs. Additionally, varying administration schedules were demonstrated to affect lymphocytes differently in vitro, either directly or via bystander activation. Furthermore, MTX and Tofa exerted different effects; while MTX showed an antiproliferative effect, Tofa marginally effected activation, although only a slight antiproliferative action, which could be potentiated by sequential treatment with MTX. Thus, it was hypothesized that these differences may be exploited in sequential therapeutic strategies, to maximize the anti‑rheumatic effect. These findings are notable and must be accounted for, as bystander‑activated cells in vivo could contribute to the spread of autoimmune activation and disease progression.

View Figures

View References

1	McGonagle D, Aziz A, Dickie LJ and McDermott MF: An integrated classification of pediatric inflammatory diseases, based on the concepts of autoinflammation and the immunological disease continuum. Pediatr Res. 65:38R–45R. 2009. View Article : Google Scholar : PubMed/NCBI
2	Uhlig T, Moe RH and Kvien TK: The burden of disease in rheumatoid arthritis. Pharmacoeconomics. 32:841–851. 2014. View Article : Google Scholar : PubMed/NCBI
3	Kremer JM, Bloom BJ, Breedveld FC, Coombs JH, Fletcher MP, Gruben D, Krishnaswami S, Burgos-Vargas R, Wilkinson B, Zerbini CA and Zwillich SH: The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum. 60:1895–1905. 2009. View Article : Google Scholar : PubMed/NCBI
4	Tanaka Y and Yamaoka K: JAK inhibitor tofacitinib for treating rheumatoid arthritis: From basic to clinical. Mod Rheumatol. 23:415–424. 2013. View Article : Google Scholar
5	Shi JG, Chen X, Lee F, Emm T, Scherle PA, Lo Y, Punwani N, Williams WV and Yeleswaram S: The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers. J Clin Pharmacol. 54:1354–1361. 2014. View Article : Google Scholar : PubMed/NCBI
6	Keystone EC, Taylor PC, Drescher E, Schlichting DE, Beattie SD, Berclaz PY, Lee CH, Fidelus-Gort RK, Luchi ME, Rooney TP, et al: Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate. Ann Rheum Dis. 74:333–340. 2015. View Article : Google Scholar
7	Wailoo A, Hernández MA, Scott IC, Ibrahim F and Scott DL: Cost-effectiveness of treatment strategies using combination disease-modifying anti-rheumatic drugs and glucocorticoids in early rheumatoid arthritis. Rheumatology (Oxford). 53:1773–1777. 2014. View Article : Google Scholar
8	Verschueren P, Esselens G and Westhovens R: Daily practice effectiveness of a step-down treatment in comparison with a tight step-up for early rheumatoid arthritis. Rheumatology (Oxford). 47:59–64. 2008. View Article : Google Scholar
9	Lee YH, Bae SC and Song GG: Comparative efficacy and safety of tofacitinib, with or without methotrexate, in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials. Rheumatol Int. 35:1965–1974. 2015. View Article : Google Scholar : PubMed/NCBI
10	Piscianz E, Valencic E, Cuzzoni E, De Iudicibus S, De Lorenzo E, Decorti G and Tommasini A: Fate of lymphocytes after withdrawal of tofacitinib treatment. PLoS One. 9:e854632014. View Article : Google Scholar : PubMed/NCBI
11	Piscianz E, Cuzzoni E, De Iudicibus S, Valencic E, Decorti G and Tommasini A: Differential action of 3-hydroxyanthranilic acid on viability and activation of stimulated lymphocytes. Int Immunopharmacol. 11:2242–2245. 2011. View Article : Google Scholar : PubMed/NCBI
12	Lyons AB, Blake SJ and Doherty KV: Flow cytometric analysis of cell division by dilution of CFSE and related dyes. Curr Protoc Cytom Chapter. 9:Unit9.11. 2013. View Article : Google Scholar
13	O'Dell JR, Mikuls TR, Taylor TH, et al: CSP 551 RACAT Investigators: Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med. 369:307–318. 2013. View Article : Google Scholar : PubMed/NCBI
14	Lee EB, Fleischmann R, Hall S, Wilkinson B, Bradley JD, Gruben D, Koncz T, Krishnaswami S, Wallenstein GV, Zang C, et al: Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med. 370:2377–2386. 2014. View Article : Google Scholar : PubMed/NCBI
15	Burmester GR, Blanco R, Charles-Schoeman C, Wollenhaupt J, Zerbini C, Benda B, Gruben D, Wallenstein G, Krishnaswami S, Zwillich SH, et al: Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: A randomised phase 3 trial. Lancet. 381:451–460. 2013. View Article : Google Scholar : PubMed/NCBI
16	Maeshima K, Yamaoka K, Kubo S, Nakano K, Iwata S, Saito K, Ohishi M, Miyahara H, Tanaka S, Ishii K, et al: The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-γ and interleukin-17 production by human CD4+ T cells. Arthritis Rheum. 64:1790–1798. 2012. View Article : Google Scholar
17	Cope AP, Schulze-Koops H and Aringer M: The central role of T cells in rheumatoid arthritis. Clin Exp Rheumatol. 25(5 Suppl 46): S4–S11. 2007.PubMed/NCBI
18	Brennan FM, Smith NM, Owen S, Li C, Amjadi P, Green P, Andersson A, Palfreeman AC, Hillyer P, Foey A, et al: Resting CD4+ effector memory T cells are precursors of bystander-activated effectors: A surrogate model of rheumatoid arthritis synovial T-cell function. Arthritis Res Ther. 10:R362008. View Article : Google Scholar : PubMed/NCBI
19	Kobayashi M, Yasui N, Ishimaru N, Arakaki R and Hayashi Y: Development of autoimmune arthritis with aging via bystander T cell activation in the mouse model of Sjögren's syndrome. Arthritis Rheum. 50:3974–3984. 2004. View Article : Google Scholar : PubMed/NCBI
20	Kobari Y, Misaki Y, Setoguchi K, Zhao W, Komagata Y, Kawahata K, Iwakura Y and Yamamoto K: T cells accumulating in the inflamed joints of a spontaneous murine model of rheumatoid arthritis become restricted to common clonotypes during disease progression. Int Immunol. 16:131–138. 2004. View Article : Google Scholar
21	VanderBorght A, Geusens P, Raus J and Stinissen P: The autoimmune pathogenesis of rheumatoid arthritis: Role of autoreactive T cells and new immunotherapies. Semin Arthritis Rheum. 31:160–175. 2001. View Article : Google Scholar : PubMed/NCBI